Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements

This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chlo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacokinetics 1996-10, Vol.31 (4), p.257-274
Hauptverfasser: DUCHARME, J, FARINOTTI, R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 274
container_issue 4
container_start_page 257
container_title Clinical pharmacokinetics
container_volume 31
creator DUCHARME, J
FARINOTTI, R
description This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.
doi_str_mv 10.2165/00003088-199631040-00003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78491959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78491959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-d5a573d294bf5e803201851b7b481cab79e989e107c42f7a58b8ecadcf1ffad93</originalsourceid><addsrcrecordid>eNo9kE1PxCAQhonRrOvqTzDhYLxV-SgteDMbV0028aJemymFLNqWFVoT_72sW5fLkHeegcmDEKbkhtFC3JJ0OJEyo0oVnJKcZH_REZpTWqoUs-IYzQmnLBOJOEVnMX4kQjJCZmgmpSpUzufofdm63mlo8XYDoQPtP11vBqcjhr7BnRmg9q2LHfYW603rg_8aE4Hv8MrrMWLf42C06QcMzTf02nTpHs_RiYU2moupLtDb6uF1-ZStXx6fl_frTHOihqwRIEreMJXXVhhJOCNUClqXdS6phrpURkllKCl1zmwJQtbSaGi0pdZCo_gCXe_f3e72MnGoOhe1aVvojR9jVcpcUSV2oNyDOvgYg7HVNrgOwk9FSbVTWv0rrQ5K91EavZz-GOvONIfByWHqX019iEmkDcmCiweMs5wpmvNfi1h_RA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78491959</pqid></control><display><type>article</type><title>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>DUCHARME, J ; FARINOTTI, R</creator><creatorcontrib>DUCHARME, J ; FARINOTTI, R</creatorcontrib><description>This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-199631040-00003</identifier><identifier>PMID: 8896943</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimalarials - metabolism ; Antimalarials - pharmacokinetics ; Antiparasitic agents ; Biological and medical sciences ; Chloroquine - metabolism ; Chloroquine - pharmacokinetics ; Humans ; Malaria - drug therapy ; Malaria - metabolism ; Medical sciences ; Pharmacology. Drug treatments ; Stereoisomerism ; Tissue Distribution</subject><ispartof>Clinical pharmacokinetics, 1996-10, Vol.31 (4), p.257-274</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3242914$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8896943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DUCHARME, J</creatorcontrib><creatorcontrib>FARINOTTI, R</creatorcontrib><title>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.</description><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimalarials - metabolism</subject><subject>Antimalarials - pharmacokinetics</subject><subject>Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Chloroquine - metabolism</subject><subject>Chloroquine - pharmacokinetics</subject><subject>Humans</subject><subject>Malaria - drug therapy</subject><subject>Malaria - metabolism</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Stereoisomerism</subject><subject>Tissue Distribution</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PxCAQhonRrOvqTzDhYLxV-SgteDMbV0028aJemymFLNqWFVoT_72sW5fLkHeegcmDEKbkhtFC3JJ0OJEyo0oVnJKcZH_REZpTWqoUs-IYzQmnLBOJOEVnMX4kQjJCZmgmpSpUzufofdm63mlo8XYDoQPtP11vBqcjhr7BnRmg9q2LHfYW603rg_8aE4Hv8MrrMWLf42C06QcMzTf02nTpHs_RiYU2moupLtDb6uF1-ZStXx6fl_frTHOihqwRIEreMJXXVhhJOCNUClqXdS6phrpURkllKCl1zmwJQtbSaGi0pdZCo_gCXe_f3e72MnGoOhe1aVvojR9jVcpcUSV2oNyDOvgYg7HVNrgOwk9FSbVTWv0rrQ5K91EavZz-GOvONIfByWHqX019iEmkDcmCiweMs5wpmvNfi1h_RA</recordid><startdate>19961001</startdate><enddate>19961001</enddate><creator>DUCHARME, J</creator><creator>FARINOTTI, R</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19961001</creationdate><title>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</title><author>DUCHARME, J ; FARINOTTI, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-d5a573d294bf5e803201851b7b481cab79e989e107c42f7a58b8ecadcf1ffad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimalarials - metabolism</topic><topic>Antimalarials - pharmacokinetics</topic><topic>Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Chloroquine - metabolism</topic><topic>Chloroquine - pharmacokinetics</topic><topic>Humans</topic><topic>Malaria - drug therapy</topic><topic>Malaria - metabolism</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Stereoisomerism</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DUCHARME, J</creatorcontrib><creatorcontrib>FARINOTTI, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DUCHARME, J</au><au>FARINOTTI, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>1996-10-01</date><risdate>1996</risdate><volume>31</volume><issue>4</issue><spage>257</spage><epage>274</epage><pages>257-274</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>8896943</pmid><doi>10.2165/00003088-199631040-00003</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0312-5963
ispartof Clinical pharmacokinetics, 1996-10, Vol.31 (4), p.257-274
issn 0312-5963
1179-1926
language eng
recordid cdi_proquest_miscellaneous_78491959
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antimalarials - metabolism
Antimalarials - pharmacokinetics
Antiparasitic agents
Biological and medical sciences
Chloroquine - metabolism
Chloroquine - pharmacokinetics
Humans
Malaria - drug therapy
Malaria - metabolism
Medical sciences
Pharmacology. Drug treatments
Stereoisomerism
Tissue Distribution
title Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A47%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20pharmacokinetics%20and%20metabolism%20of%20chloroquine%20:%20Focus%20on%20recent%20advancements&rft.jtitle=Clinical%20pharmacokinetics&rft.au=DUCHARME,%20J&rft.date=1996-10-01&rft.volume=31&rft.issue=4&rft.spage=257&rft.epage=274&rft.pages=257-274&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-199631040-00003&rft_dat=%3Cproquest_cross%3E78491959%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78491959&rft_id=info:pmid/8896943&rfr_iscdi=true